

1 Longitudinal trajectories of muscle impairments in growing boys with
2 Duchenne muscular dystrophy

3

4

5 Ines Vandekerckhove¹ – Marleen Van den Hauwe^{1,2} – Tijl Dewit^{1,3} – Geert Molenberghs^{4,5} – Nathalie
6 Goemans^{2,6} – Liesbeth De Waele^{2,6} – Anja Van Campenhout^{6,7} – Friedl De Groote⁸ – Kaat Desloovere^{1,3*}

7

8

9

10

11 ¹Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium

12 ²Department of Child Neurology, University Hospital Leuven, Leuven, Belgium

13 ³Clinical Motion Analysis Laboratory, University Hospital Leuven, Pellenberg, Belgium

14 ⁴Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), KU Leuven, Leuven,
15 Belgium

16 ⁵Interuniversity Institute for Biostatistics and Statistical Bioinformatics (I-BioStat), Data Science
17 Institute, Hasselt University, Hasselt, Belgium

18 ⁶Department of Development and Regeneration, KU Leuven, Leuven, Belgium

19 ⁷Department of Orthopedics, University Hospital Leuven, Leuven, Belgium

20 ⁸Department of Movement Sciences, KU Leuven, Leuven, Belgium

21

22

23

24

25 *** Corresponding author**

26 E-mail: kaat.desloovere@kuleuven.be (KD)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Abstract

28 Background

29 Insights into the progression of muscle impairments in growing boys with Duchenne muscular
30 dystrophy (DMD) remains incomplete due to the frequent oversight of normal maturation as
31 confounding factor, thereby restricting the delineation of sole pathological processes.

32 Objective

33 To establish longitudinal trajectories for a comprehensive integrated set of muscle impairments,
34 including muscle weakness, contractures and muscle size alterations, whilst correcting for normal
35 maturation, in DMD.

36 Methods

37 Thirty-five boys with DMD (aged 4.3-17 years) were included. Fixed dynamometry, goniometry and 3D
38 freehand ultrasound were used to repeatedly assess lower limb muscle strength, passive range of
39 motion (ROM) and muscle size, resulting in 165, 182 and 67 assessments for the strength, ROM and
40 ultrasound dataset, respectively. To account for natural strength development, ROM reduction and
41 muscle growth in growing children, muscle impairments were converted to unit-less z-scores
42 calculated in reference to typically developing (TD) peers. This allows the interpretation of the muscle
43 impairments as deficits or alterations with respect to TD. Mixed-effect models estimated the
44 longitudinal change in muscle impairments.

45 Results

46 The pathological trajectories of most muscle impairments with age followed a similar non-linear,
47 piecewise pattern, characterized by an initial phase of improvement or stability lasting until 6.6-9.5
48 years, and a subsequent decline after these ages. The muscle strength outcomes and several ROMs

49 showed already initial deficits at young ages. General muscle weakness and plantar flexion
50 contractures exhibited the steepest declines, resulting in large deficits at older ages. The muscle size
51 alterations with age were muscle-specific.

52 Conclusions

53 The established longitudinal trajectories of muscle impairments will serve as the basis to enhance
54 understanding of their relationship with the progressive gait pathology in DMD. Our study provides
55 outcome measures, which will be useful for future clinical trials that assess the efficacy of novel
56 therapeutic strategies.

57

58 Introduction

59 Duchenne muscular dystrophy (DMD) is an X-linked progressive muscular disorder, affecting one per
60 3,500-6,000 newborn boys [1–3]. It causes dystrophin deficiency that increases muscle cell membrane
61 fragility and vulnerability to contraction-induced damage [4–6]. Progressive muscle degeneration then
62 emerges with loss of contractile tissue and replacement by fat and fibrotic tissue [2,7]. Boys with DMD
63 exhibit progressive muscle impairments, including muscle size alterations, weakness and contractures
64 [1,2,8,9]. These muscle impairments contribute to alterations in posture and gait, reflected in a motor
65 function decline with loss of ambulation between the ages of 7.1 and 18.6 years (mean age: 12.7 years)
66 [1,2,10]. The state-of-the-art standard of care has altered the natural disease course and has increased
67 life expectancy in DMD [2,11–14]. One of the treatment goals in DMD is prolonging ambulation [1,2].
68 However, previous studies showed conflicting results on orthopedic and orthotic interventions that
69 aim at optimizing gait and motor performance [15–19]. Since many treatment options target muscle
70 impairments, an improved understanding of how underlying muscle impairments contribute to gait
71 pathology in DMD is essential to improve clinical decision making and to make progress in
72 rehabilitation, orthotic and orthopedic treatments. Furthermore, promising novel clinical trials could
73 potentially slow down disease progression and delay loss of ambulation, but their clinical development
74 has been hampered due to the lack of sensitive outcome measures and natural history data [20–23].
75 To these ends, we first need to establish longitudinal trajectories of muscle impairments. This will
76 enrich natural history data and reveal sensitive outcome measures, and may eventually be used to
77 enhance our understanding of their relationship with progressive gait pathology.

78
79 Progressive muscle weakness is the primary clinical symptom in DMD. McDonald et al.[24] reported
80 that muscle strength declined at an average rate of -0.25 manual muscle testing (MMT) units over 20
81 muscle groups of the neck, trunk, upper and lower limb, over a period of one year, in boys aged
82 between 5 and 13 years. However, MMT is rather subjective and appears to have restricted reliability,

83 accuracy and sensitivity [25–27]. Objective dynamometry is, therefore, preferred for evaluating muscle
84 weakness [28]. Significant weakness, evaluated through dynamometry, has been observed already in
85 young boys with DMD and the strength deficit relative to typically developing (TD) children increased
86 further with age [28–30]. This was primarily the result of the large age-related increase in muscle
87 strength in TD, while in DMD absolute muscle strength remained relatively constant between the ages
88 of 5 and 14 years [28,30]. After accounting for growth by normalizing muscle strength to body surface
89 area or body mass, a significant reduction in strength with age was detected in boys with DMD [28,29].
90 Additionally, the use of more complex statistical models, such as non-linear piecewise models, showed
91 that absolute muscle strength increased or remained stable until 8.5 years and then declined with age
92 [31]. Moreover, mostly cross-sectional analyses have been performed, and therefore, caution is
93 needed with interpreting cross-sectional age-effect as longitudinal disease progression. A previous
94 longitudinal analysis indicated that absolute knee extension/flexion strength increased until the age of
95 7.5 years, while after the age of 7.5 years strength declined, with even a more pronounced decline
96 after 9 years of age [31]. Recently, Leon et al.[32] generated percentile curves of muscle strength for
97 boys with DMD aged 4 to 18 years based on an extended longitudinal dataset consisting of 230
98 assessments in 73 boys. Knee extension strength exhibited the most pronounced decline, followed by
99 hip flexion strength, and then knee flexion strength. A recent 8-year longitudinal study of Buckon et
100 al.[33] delineated the progressive muscle weakness in boys with DMD (aged 4 to 15 years at baseline),
101 comparing those treated with corticosteroids (n=70) and those who were treatment-naïve (n=14).
102 They found that knee extension strength, followed by hip extension strength, declined fastest and,
103 that corticosteroid therapy slowed the rate of decline in knee extension strength by three times
104 compared to treatment-naïve boys.

105

106 Apart from progressive muscle weakness, also other impairments occur in boys with DMD. Due to fat
107 and fibrotic tissue infiltration into the muscles, prolonged static positioning and muscle weakness, boys
108 with DMD experience progressive loss of passive range of motion (ROM), resulting in the development

109 of contractures [8]. Whereas ankle plantar flexion contractures develop first, hip flexion, knee flexion
110 and hip abduction contractures are also frequently present in boys with DMD [8,24,34]. In general,
111 lower limb contractures are strongly related to wheelchair reliance [8,24,34,35]. Even though boys
112 with DMD are longer ambulant with the widespread use of corticosteroids [36], the pattern of slow
113 contracture evolution prior to loss of ambulation and rapid contracture evolution following loss of
114 ambulation has persisted [24,34,35]. Choi et al.[35] found that 52.6% in the ambulatory group had
115 ankle plantar flexion contractures and Willcocks et al.[34] showed that ROM was significantly lower in
116 DMD than in TD, 5 years prior to loss of ambulation at the ankle, 2 years prior to loss of ambulation at
117 the knee and 4 years prior to loss of ambulation at the hip. However, most studies focused on
118 frequency and severity of contractures, while a quantification of the progression rate of decreasing
119 ROM based on large longitudinal datasets is scarce. The longitudinal picture of contracture
120 development and impact of treatment is important to be outlined, to relate these changes with the
121 progressive gait pathology. Based on an extended longitudinal study of 1761 assessments in 322 boys
122 with DMD, Kiefer et al.[37] found that ankle dorsiflexion ROM decreased with 1.43 degrees per year.
123 Furthermore, Leon et al.[32] generated percentile curves for ankle dorsiflexion ROM with knee flexed
124 and extended based on a longitudinal dataset of 258 assessments in 73 boys with DMD. The ankle
125 dorsiflexion ROM gradually declined with age. Negative ROM values (i.e., ROM deficit to reach the
126 neutral ankle angle of 90°) were observed from 8 years onwards with knee extended and from 9 years
127 onwards with knee flexed, highlighting a pathological shortening in ankle plantar flexors [32]. However,
128 previous studies did not account for the typical reduction in ROM observed in TD children aged 2 to 17
129 years [38–40].

130
131 The progressive loss of contractile tissue and proliferation of fat and fibrotic tissue result in varying
132 muscle size alterations, such as profound atrophy in some muscles and (pseudo)hypertrophy in others
133 [9]. (Pseudo)hypertrophy of the m. triceps surae is a well-known feature in DMD with reported similar
134 contractile cross-sectional area (CSA) as in TD [9] but a total CSA up to 60% larger than in TD [28]. Yet,

135 results on the change in m. triceps surae size with age in DMD are conflicting [9,28]. The m. quadriceps
136 has been characterized by atrophy in DMD, with both smaller contractile and total CSA than in TD [9].
137 However, Mathur et al.[28] found hypertrophy of the m. quadriceps under the age of 10 years and
138 atrophy from the age of 11 years. While the m. triceps surae and m. quadriceps represent two ends of
139 a spectrum, the m. hamstrings and m. tibialis anterior presented with less distinctive muscle size
140 alterations [9]. Magnetic resonance imaging (MRI) has been frequently used to quantify muscle size as
141 well as composition and has repeatedly been suggested as sensitive biomarker in DMD clinical trials
142 [41–45]. Ultrasound has some advantages over MRI, since it is child-friendly, relatively cheap, fast,
143 does not require sedation, and is clinically easily accessible because it can be collected using a portable
144 device. Ultrasound studies showed that changes in muscle echo-intensity preceded motor regression
145 and increased over time, highlighting the added value of ultrasound as practical and child-friendly
146 estimate of muscle composition as an outcome measure for the longitudinal follow-up of disease
147 progression [46–48]. However, studies evaluating muscle size with ultrasound in DMD are scarce. Bulut
148 et al.[49] reported increased muscle thickness of the m. vastus lateralis and m. medial gastrocnemius
149 in children with DMD compared to TD children. However, Jansen et al.[47] and Pillen et al.[50] only
150 found a reduced muscle thickness of the m. quadriceps muscle at baseline without abnormalities in
151 thickness of the other muscles. Morse et al.[51] even showed a decrease of 36% in CSA of the m. medial
152 gastrocnemius in adults with DMD compared to TD adults. Additionally, a longitudinal analysis
153 indicated that muscle thickness normalized to body mass of the lower limb muscles did not progress
154 with age [47], while another study demonstrated larger absolute muscle thickness of the m. medial
155 gastrocnemius in more severely affected boys than in less severely affected boys [49]. This highlights
156 that the longitudinal evolution of muscle size alterations measured by ultrasound in growing boys with
157 DMD is still unclear.

158

159 It can be concluded that the insights into the progression of muscle impairments in boys with DMD
160 during growth remain incomplete. This inadequacy arises from the fact that not all lower-limb muscle

161 groups have undergone comprehensive assessment, and conflicting results among studies have been
162 reported. Additionally, the confounding factor of normal maturation has frequently been overlooked,
163 or various normalization techniques have been inconsistently applied. Therefore, it has been difficult
164 to distinguish pathological changes from typical strength development, ROM reduction, and muscle
165 growth observed in TD, hampering the interpretation of pure pathological processes during growth in
166 DMD. We recently developed anthropometric-related TD percentile curves for muscle strength and
167 size [52]. These curves enable us to convert individual muscle strength and size outcomes into unit-
168 less z-scores, which indicate deficits relative to TD peers. Since this way typical strength development
169 and normal muscle growth are accounted for, the use of z-scores facilitates the interpretation of
170 pathological alterations during growth. Similarly, the TD reference values of Mudge et al.[38] and
171 Sankar et al.[39] for three age groups can be used to calculate unit-less z-scores for ROM, allowing to
172 correct for the typical reduction in ROM observed in TD. Therefore, the aim of this study was to
173 establish longitudinal trajectories for a comprehensive integrated set of muscle impairments, including
174 muscle weakness, contractures, and muscle size alterations, whilst correcting for normal maturation,
175 in growing boys with DMD through a longitudinal follow-up design.

176 **Materials and methods**

177 **Study design and participants**

178 This longitudinal observational cohort study was designed with a protocol of repeated assessments
179 with a variable number of assessments between participants and variable time intervals between
180 assessments.

181 Children with DMD were recruited via the multidisciplinary clinic of the Neuromuscular Reference
182 Centre (NMRC) in the University Hospital Leuven campus Gasthuisberg between 22 June 2018 and 31
183 December 2022. Boys aged between 3 and 16 years at baseline, ambulatory for at least 100 meters,
184 and with a confirmed genetic diagnosis of DMD, were included. Cognitive and behavioral disorders

185 preventing accurate measurements, a clinical picture of Becker muscular dystrophy, and history of
186 muscle lengthening surgery were exclusion criteria. Use of corticosteroids and participation in clinical
187 trials were permitted. At the University Hospital Leuven, a proactive/preventive policy was
188 implemented to address contractures. Hereto, night-time ankle foot orthoses (AFOs) were initiated
189 before any contractures occurred, often in conjunction with the start of corticosteroids. Occasionally,
190 serial casting was also employed to manage early losses in ankle dorsiflexion ROM.

191 Retrospective data from the included children collected before 14 June 2018 (between 20 May 2015
192 and 14 June 2018) was accessed through the database of University Hospital Leuven between 22 June
193 2018 and 31 December 2022.

194 The local ethics committee (Ethical Committee UZ Leuven/KU Leuven; S61324) approved this study
195 under the Declaration of Helsinki. All methods were performed in accordance with the relevant
196 guidelines and regulations. The parents or caregivers of the participants signed a written informed
197 consent and participants aged 12 years or older signed a written informed assent.

198

199 Data collection and analysis

200 Muscle strength and size were collected unilaterally. The weakest side based on MMT was selected as
201 the assessed side. Contractures were assessed bilaterally, but only the values of the weakest side were
202 included in further analyses, to ensure consistency with the other measurements. If no weakest side
203 could be identified, the assessed side was randomly chosen.

204 Anthropometry

205 Body mass, height and lower limb segment lengths of the boys with DMD were measured at each
206 follow-up session.

207 Muscle weakness

208 A reliable and valid instrumented strength assessment was used to evaluate muscle weakness of the
209 hip extensors, hip flexors, hip abductors, knee extensors, knee flexors, plantar flexors, and dorsiflexors

210 [53,54]. The participants performed maximal voluntary isometric contractions (MVIC) using a fixed
211 dynamometer (MicroFet, Hogan Health Industries, West Jordan, UT United States) in a standardized
212 test position. Custom-written matlab (The Mathworks Inc., Natick, M.A., R2021b) scripts were used to
213 extract the maximal force (in Newton) per MVIC and to calculate the mean maximal joint torque (in
214 Newton meter) per muscle group by multiplying the mean maximal force over one to three
215 representative MVIC trials with the lever arm, which was determined as 75% of the segment length.
216 To account for typical strength development, anthropometric-related TD percentile curves for muscle
217 strength (n=153) were used to convert mean maximal joint torques into unit-less z-scores [52]. Hence,
218 these z-scores reflect muscle strength deficits with respect to TD peers.

219 Contractures

220 During a standardized clinical examination, goniometry was used to measure the passive ROM of hip
221 extension (modified Thomas test [38]), hip adduction (with extended hip and knee of the assessed leg
222 and hip and knee flexed in 90° of the contralateral leg), knee extension [38], hamstrings (true popliteal
223 angle [38]), and ankle dorsiflexion (with knee extended and knee flexed in 90° [38]). Previous studies
224 reported acceptable intra-rater and inter-rater reliability of these measures [38]. Passive ROM was
225 measured in degrees. Since TD percentile curves for ROM are currently lacking, the age-related
226 normative reference values of Mudge et al.[38] were used to convert ROM measures into unit-less z-
227 scores, accounting for the typical reduction in passive ROM during growth. Thereby, the normative
228 mean of the corresponding age group (4-7 years, 8-11 years and 12-16 years) was subtracted from the
229 individual ROM and then this difference was divided by the standard deviation of the total normative
230 group. We decided to use the standard deviation of the total normative group, since the large
231 difference in standard deviations between normative age groups would result in unrealistic changes in
232 z-scores over time. A similar approach was used to calculate z-scores for hip adduction ROM, but based
233 on the reference values for three age groups provided by Sankar et al.[39], since these were lacking in
234 the study of Mudge et al.[38]. By calculating the z-scores based on data for three age groups,

235 continuous changes with age were not fully controlled for, influencing the validity of z-scores.
236 Therefore, both absolute ROM (in degrees) and unit-less ROM (in z-scores) were reported.

237 Muscle size alterations

238 The reliable 3D freehand ultrasonography (3DfUS) was used to assess muscle size alterations of the m.
239 rectus femoris, m. medial gastrocnemius and m. tibialis anterior [55,56]. The orientation and position
240 of 2D ultrasound images were quantified using a motion tracking system (Optitrack V120:Trio,
241 NaturalPoint Inc., Corvallis, Oregon, USA) that tracked four reflective markers on the linear probe of a
242 Telemed-Echoblaster B-mode ultrasound device (Telemed-Echoblaster 128 Ext-1Z, with a 5.9-cm 10-
243 MHz linear US transducer, Telemed Ltd., Vilnius, Lithuania). To limit muscle deformation, a custom-
244 made gel pad (i.e., the portico), was attached on the ultrasound probe [57]. Data was collected and
245 processed using STRADWIN software (version 6.0; Mechanical Engineering, Cambridge University,
246 Cambridge, UK). The Euclidean distances between relevant anatomical landmarks were calculated to
247 estimate muscle lengths (in mm). Mid-belly anatomical CSA (in mm²) was defined by one manually
248 drawn transverse plane segmentation alongside the inner muscle border at 50% of the muscle length.
249 We applied the same ultrasound settings and parameter definition as reported in previous studies
250 [56,58]. In some children, high muscle degeneration strongly reduced the visibility of the muscle
251 border. In those children, a single 2D image was collected at the mid-belly. Real-time feedback from
252 the ultrasound images and palpation of the leg were used to identify landmarks. Subsequently, a tape
253 measure was used to determine the midpoint between landmarks (i.e., mid-belly). To account for
254 typical muscle growth, anthropometric-related TD percentile curves for muscle CSA (n=143) were used
255 to convert CSA into unit-less z-scores [52]. Hence, these z-scores reflect muscle size alterations with
256 respect to TD peers.

257

258 Statistical analysis

259 To model the longitudinal change in muscle impairments, (non-)linear mixed-effect models were used.

260 Mixed models were fitted per outcome, i.e., strength of the 7 muscle groups (expressed as z-scores),
261 6 passive ROMs (absolute (in degrees) as well as unit-less (in z-scores)) and 3 muscle CSAs (expressed
262 in z-scores). The mixed models consisted of a mean structure (i.e., fixed effects) to delineate the
263 average trajectory and a covariance structure, induced by random effects, to describe the inter-subject
264 variability. Age (expressed in years) at each repeated assessment represented the time-effect and was
265 selected as the fixed effect. Random effects were included to model the variability in starting point
266 (i.e., random intercept) and the variability in trajectory (i.e., random slope) among the subjects. We
267 applied the previously documented workflow to construct the mixed-effect models [59–61]. Since the
268 explorations suggested linear trends interrupted by breaking points, non-linear piecewise models were
269 allowed. Thereby, estimated values from the explorations were used as starting values and the
270 presence of multiple breakpoints was investigated. A breakpoint was defined if the F-test detected a
271 significant change between adjacent slopes, whilst ensuring a minimum of 10 datapoints per
272 regression line. Moreover, a breakpoint was not interpreted as a strict age where a change occurs, but
273 rather as the approximate age around which a change in rate occurs. Non-nested linear and non-linear
274 piecewise models were compared using the Akaike information criterion (AIC). Since, overall, the
275 piecewise models demonstrated the smallest AIC, these models were selected. Yet, the difference with
276 the linear models was small and we therefore documented the linear models in the supplementary
277 materials (S1-S3 Figs and S1-S3 Tables). The piecewise model with observation j in subject i to estimate
278 the outcome $_{ij}$ was defined as follows:

279

$$280 \text{ Outcome}_{ij} = (\alpha_0 + a_{i0}) + (\beta_1 + b_{i1}) * age_{ij} + \varepsilon_{ij} \quad \text{if } age_{ij} < \gamma_1$$

$$281 \text{ Outcome}_{ij} = (\alpha_0 + a_{i0}) + \gamma_1 * ((\beta_1 + b_{i1}) - (\beta_2 + b_{i2})) + (\beta_2 + b_{i2}) * age_{ij} + \varepsilon_{ij} \quad \text{if } \gamma_1 \leq age_{ij} < \gamma_2$$

$$282 \text{ Outcome}_{ij} = (\alpha_0 + a_{i0}) + \gamma_1 * ((\beta_1 + b_{i1}) - (\beta_2 + b_{i2})) + \gamma_2 * ((\beta_2 + b_{i2}) - (\beta_3 + b_{i3})) \\ + (\beta_3 + b_{i3}) * age_{ij} + \varepsilon_{ij} \quad \text{if } \gamma_2 \leq age_{ij}$$

283

284 with α_0 = intercept; a_{i0} = random intercept; β_1 = regression slope if $age_{ij} < \gamma_1$; b_{i1} = random slope of β_1 ;

285 γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \leq age_{ij} < \gamma_2$; b_{i2} = random slope of β_2 ; γ_2 = second

286 breakpoint; β_3 = regression slope if $\gamma_2 \leq \text{age}_{ij}$; b_{i3} = random slope of β_3 ; γ_1 = first breakpoint; ϵ_{ij} =
287 measurement error.

288 F-tests were performed to investigate if the intercepts, regression slopes and breakpoints differed
289 from zero. The significance threshold was set to $\alpha = 0.05$. So-called empirical Bayes estimates were
290 calculated after model formulation and used to detect outliers, i.e., subjects with an exceptional
291 starting point and/or evolution with age. Data of outliers were checked. SAS® (version 9.4, Statistical
292 Analysis Software, SAS Institute Inc., Cary, NC, USA) was used to conduct all analyses and visualizations.

293 Results

294 Thirty-five boys with DMD, aged between 4.3 and 17 years old, were repeatedly measured between
295 2015 and 2022 at multiple time points (1 to 11) with a variable time interval of 5-35 months, covering
296 a follow-up period of 6 months to 6.6 years. In total, the collected dataset consisted of 185
297 observations (Table 1 and S4 Fig). After data collection and processing, quality check and outliers
298 removal, the strength dataset consisted of 165 observations in 33 boys, the ROM dataset of 182
299 observations in 34 boys and the ultrasound dataset of 67 observations in 34 boys.

300

301 **Table 1. Group demographics**

Baseline characteristics	
Subjects (n)	35
Median age (Q1-Q3)	7.6 years (4.9-9.9)
Median body mass (Q1-Q3)	22.4 kg (18.3-33.8)
Median height (Q1-Q3)	1.16 m (1.01-1.29)
Median BMI (Q1-Q3)	17.1 kg/m ² (15.5-19.1)
Corticosteroids	
Daily Deflazacort (% subjects)	77.10%
Vamorolone (% subjects)	/
No steroids (% subjects)	22.90%
Participation in clinical trial with disease modifying medication (% subjects)	20%
Adherence night-time ankle foot orthoses (% subjects)	82.90%
Serial casting (% subjects)	2.90%
Characteristics over all observations	
Subjects (n)	35
Observations (n)	185
Median age (Q1-Q3)	10.1 years (7.6-12.5)
Median body mass (Q1-Q3)	30.4 kg (22.4-40.4)
Median height (Q1-Q3)	1.23 m (1.14-1.31)
Median BMI (Q1-Q3)	18.9 kg/m ² (16.8-24.1)
Corticosteroids	
Daily Deflazacort (% observations)	92.40%
Vamorolone (% observations)	2.20%
No steroids (% observations)	5.40%
Participation in clinical trial with disease modifying medication (% observations)	36.80%
Adherence night-time ankle foot orthoses (% observations)	78.90%
Serial casting (% observations)	6.50%
Loss of ambulation (% subjects)	31.40%

302

303 Muscle weakness

304 The longitudinal trajectories of muscle strength deficits were characterized by piecewise trends (Fig 1
305 and Table 2). Hip extension strength tended to increase with a rate of 0.93 z-score/year from a z-score
306 of -3.6 z-score at 4.9 years to a z-score of -2 at age 6.6 years and then decreased with a rate of -0.29 z-
307 score/year until a z-score of -4.9 at 16.4 years. Hip flexion strength increased with 1.03 z-score/year
308 from -2.5 z-score at age 4.9 years to -0.7 z-score at age 6.7 years and then decreased with -0.29 z-
309 score/year until -3.5 z-score at age 16.4 years. Hip abduction strength was -2.2 z-score at age 4.9 years
310 and remained constant until age 8.5 years. It then decreased with -0.44 z-score/year from -1.5 z-score
311 at age 8.5 years to -5 z-score at age 16.4 years. Knee extension strength was -0.7 z-score at age 4.6
312 years and remained constant until age 7.3 years. It then decreased with -0.48 z-score/year from -0.4
313 z-score at age 7.3 years to -4.8 z-score at age 16.4 years. Knee flexion strength was -1.5 z-score at age

314 4.6 years and remained constant until 8.6 years. It then decreased with a rate of -0.25 z-score/year
315 from -1.3 z-score at age 8.6 years to -3.2 z-score at age 16.4 years. Ankle plantar flexion tended to
316 increase with a rate of 0.25 z-score/year from -2.1 z-score at age 4.6 years to -1 z-score at age 9.1 years
317 and then decreased with -0.39 z-score/year until -3.8 z-score at age 16.4 years. Ankle dorsiflexion
318 strength was -2.3 z-score at age 4.6 years and remained constant until age 8.5 years. It then decreased
319 with -0.33 z-score/year from -1.8 z-score at age 8.5 years to -4.5 z-score at age 16.4 years.

320

321 **Fig 1. Predicted longitudinal trajectories for muscle strength deficits of hip muscles (a), knee muscles**
322 **(b) and ankle muscles (c) with age for boys with DMD.** The average predicted trajectory (black tick
323 line), the individual predicted profiles (colored thinner lines), and the actual observed outcomes
324 (colored dots) are displayed. Each color represents one patient with DMD. The estimates for the fixed
325 effects are given in Table 1. DMD, Duchenne muscular dystrophy

326 **Table 2. Fixed effects of piecewise models for the longitudinal trajectories of the muscle strength deficits with age for boys with DMD**

Outcomes	n subj	n obs	Regression coefficients (β) and breakpoints (γ)			
			Intercept α_0 (CI) <i>p-value</i>	β_1 (CI) <i>p-value</i>	γ_1 (CI) <i>p-value</i>	β_2 (CI) <i>p-value</i>
Hip extension strength (z-score)	33	144	-8.16 (-13.91 -2.40) 0.0070	0.93 (-0.05 1.90) 0.0613	6.61 (5.85 7.37) <0.0001	-0.29 (-0.48 -0.09) 0.0061
Hip flexion strength (z-score)	33	144	-7.51 (-12.16 -2.87) 0.0024	1.03 (0.23 1.83) 0.0131	6.66 (5.90 7.41) <0.0001	-0.29 (-0.41 -0.16) <0.0001
Hip abduction strength (z-score)	33	143	-3.12 (-5.01 -1.23) 0.0020	0.19 (-0.08 0.47) 0.1654	8.52 (7.26 9.78) <0.0001	-0.44 (-0.57 -0.32) <0.0001
Knee extension strength (z-score)	33	165	-1.18 (-2.19 -0.17) 0.0234	0.10 (-0.05 0.26) 0.1813	7.31 (6.43 8.18) <0.0001	-0.48 (-0.60 -0.36) <0.0001
Knee flexion strength (z-score)	33	165	-1.78 (-4.16 0.61) 0.1389	0.06 (-0.23 0.34) 0.6953	8.63 (8.63 8.63) <0.0001	-0.25 (-0.33 -0.17) <0.0001
Plantar flexion strength (z-score)	33	165	-3.22 (-5.15 -1.29) 0.0019	0.25 (-0.02 0.51) 0.0674	9.05 (7.80 10.29) <0.0001	-0.39 (-0.58 -0.20) 0.0003
Dorsiflexion strength (z-score)	33	165	-2.86 (-4.90 -0.83) 0.0073	0.12 (-0.16 0.40) 0.3817	8.45 (7.58 9.32) <0.0001	-0.33 (-0.44 -0.23) <0.0001

327 p-values in bold indicate significance level at $p < 0.05$.

328 The following symbols represent: α_0 = intercept; β_1 = regression slope if age $< \gamma_1$; γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \leq$ age.

329 CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; subj, subjects

330

331 Contractures

332 The longitudinal trajectories of the ROMs revealed a clear degeneration solely for ankle dorsiflexion
333 (Fig 2 and Table 3). The absolute ankle dorsiflexion ROM with knee extended was 8.3° at age 4.3 years
334 and remained constant until 8.1 years. It then decreased with -2.7°/year from 9.7° at age 8.1 years to
335 -8.9° at age 15.1 years, and lastly decreased with -1°/year until -10.7° at age 17 years. The unit-less
336 ankle dorsiflexion ROM with knee extended was -2.8 z-score at age 4.3 years and remained constant
337 until 8.6 years. It then decreased with -0.34 z-score/year from -2.6 z-score at age 8.6 years to -5.5 z-
338 score at age 17 years. The absolute ankle dorsiflexion ROM with knee flexed was 15.7° at age 4.3 years
339 and remained constant until age 8.1 years. It then decreased with -2.2°/year from 15° at age 8.1 years
340 to -4.7° at age 17 years. The unit-less ankle dorsiflexion ROM with knee flexed was -2 z-score at age
341 4.3 years and remained constant until 8.2 years. It then decreased with -0.24 z-score/year from -2 z-
342 score at age 8.2 years to -4.1 z-score at age 17 years. For hip extension and adduction ROM, no reliable
343 and valid mixed models could be fitted. The data exploration (S5 Fig) suggested, however, a subtle
344 downward trend for the absolute hip extension and adduction ROMs. At age 4.3 years, absolute and
345 unit-less knee extension ROMs were 2.5° and -0.5 z-score, respectively. For these outcomes, no
346 significant longitudinal change was found. Absolute hamstrings ROM was -39° at age 4.3 years, but did
347 not progress with age. Unit-less hamstrings ROM increased with 0.10 z-score/year from -1.9 z-score at
348 age 4.3 years to -0.6 z-score at age 17 years.

349
350 **Fig 2. Predicted longitudinal trajectories for absolute (left column) and unit-less (right column) knee**
351 **extension ROM (a), Hamstrings ROM (b), ankle dorsiflexion with knee extended (c) and ankle**
352 **dorsiflexion with knee flexed (d) with age for boys with DMD.** The average predicted trajectory (black
353 tick line), the individual predicted profiles (colored thinner lines), and the actual observed outcomes
354 (colored dots) are displayed. Each color represents one patient with DMD. The estimates for the fixed
355 effects are given in Table 2. DMD, Duchenne muscular dystrophy

356

Table 3. Fixed effects of piecewise models for the longitudinal trajectories of the absolute and unit-less ROMs with age for boys with DMD

Outcomes	n subj	n obs	Intercept		Regression coefficients (β) and breakpoints (γ)				
			α_0 (CI) <i>p-value</i>	β_1 (CI) <i>p-value</i>	γ_1 (CI) <i>p-value</i>	β_2 (CI) <i>p-value</i>	γ_2 (CI) <i>p-value</i>	β_3 (CI) <i>p-value</i>	
Knee extension ROM (°)	34	180	-3.62 (-12.70 5.47) <i>0.4234</i>	1.42 (-0.32 3.16) <i>0.1063</i>	7.09 (4.83 9.35) <0.0001	-0.42 (-0.97 0.14) <i>0.1374</i>			
Knee extension ROM (z-score)	34	180	-1.72 (-3.55 0.10) <i>0.0638</i>	0.28 (-0.06 0.63) <i>0.1041</i>	7.09 (4.36 9.82) <0.0001	0.01 (-0.09 0.12) <i>0.8201</i>			
Hamstrings ROM (°)	34	180	-40.92 (-50.11 -31.72) <0.0001	0.45 (-0.37 1.26) <i>0.2797</i>					
Hamstrings ROM (z-score)	34	180	-2.32 (-3.21 -1.43) <0.0001	0.10 (0.02 0.19) 0.0169					
Dorsiflexion ROM knee extended (°)	34	182	6.64 (-1.31 14.58) <i>0.0987</i>	0.38 (-0.80 1.56) <i>0.5148</i>	8.12 (6.89 9.35) <0.0001	-2.66 (-3.40 -1.92) <0.0001	15.14 (13.54 16.75) <0.0001	-0.95 (-1.87 -0.03) 0.0442	
Dorsiflexion ROM knee extended (z-score)	34	182	-2.99 (-4.34 -1.63) <0.0001	0.04 (-0.14 0.22) <i>0.6556</i>	8.58 (8.58 8.58) <0.0001	-0.34 (-0.52 -0.17) 0.0004			
Dorsiflexion ROM knee flexed (°)	34	182	16.50 (6.32 26.68) 0.0023	-0.18 (-1.61 1.25) <i>0.7965</i>	8.12 (6.39 9.85) <0.0001	-2.23 (-2.85 -1.60) <0.0001			
Dorsiflexion ROM knee flexed (z-score)	34	182	-2.09 (-3.59 -0.58) 0.0082	0.01 (-0.21 0.22) <i>0.9468</i>	8.19 (5.92 10.45) <0.0001	-0.24 (-0.33 -0.14) <0.0001			

357

p-values in bold indicate significance level at $p < 0.05$.

358

The following symbols represent: α_0 = intercept; β_1 = regression slope if age $< \gamma_1$; γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \leq$ age $< \gamma_2$; γ_2 = second

359

breakpoint; β_3 = regression slope if $\gamma_2 \leq$ age.

360

CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; ROM, range of motion; subj, subjects

361

362 Muscle size alterations

363 The longitudinal trajectories of muscle size deficits were characterized by piecewise trends (Fig 3 and
364 Table 4). The m. rectus femoris CSA was 0.6 z-score at age 4.3 years and remained constant until age
365 8.8 years. It then decreased with -0.37 z-score/year from 1 z-score at age 8.8 years to -1.7 z-score at
366 age 16.2 years. The m. medialis gastrocnemius CSA was 3 z-score at age 4.3 years and remained
367 constant until age 9.5 years. It then decreased with -0.55 z-score/year from 4 z-score at age 9.5 years
368 to -0.1 z-score at age 17 years. The m. tibialis anterior CSA increased with 0.46 z-score/year from -0.1
369 z-score at age 4.3 years to 2 z-score at age 8.8 years, then decreased with -0.45 z-score/year until 0.3
370 z-score at age 12.5 years, and lastly remained relatively constant until 0.3 z-score at age 17 years.

371

372 **Fig 3. Predicted longitudinal trajectories for muscle size deficits with age for boys with DMD.** The
373 average predicted trajectory (black tick line), the individual predicted profiles (colored thinner lines),
374 and the actual observed outcomes (colored dots) are displayed. Each color represents one patient with
375 DMD. The estimates for the fixed effects are given in Table 3. DMD, Duchenne muscular dystrophy

376 **Table 4. Fixed effects of piecewise models for the longitudinal trajectories of the muscle size alterations with age for boys with DMD**

Outcomes	n subj	n obs	Intercept		Regression coefficients (β) and breakpoints (γ)				
			α_0 (CI) <i>p-value</i>	β_1 (CI) <i>p-value</i>	γ_1 (CI) <i>p-value</i>	β_2 (CI) <i>p-value</i>	γ_2 (CI) <i>p-value</i>	β_3 (CI) <i>p-value</i>	
Rectus femoris CSA (z-score)	24	46	0.08 (-1.75 1.91) <i>0.9259</i>	0.11 (-0.16 0.37) <i>0.3994</i>	8.77 (6.58 10.97) <0.0001	-0.37 (-0.62 -0.12) 0.0057			
Medial gastrocnemius CSA (z-score)	34	67	2.16 (-1.87 6.19) <i>0.2840</i>	0.20 (-0.32 0.72) <i>0.4410</i>	9.46 (7.71 11.21) <0.0001	-0.55 (-0.89 -0.21) 0.0024			
Tibialis anterior CSA (z-score)	29	64	-2.08 (-4.64 0.48) <i>0.1072</i>	0.46 (0.11 0.81) 0.0116	8.82 (7.77 9.87) <0.0001	-0.45 (-0.68 -0.22) 0.0004	12.47 (12.47 12.47) <0.0001	-0.01 (-0.25 0.22) <i>0.9072</i>	

377 p-values in bold indicate significance level at $p < 0.05$.

378 The following symbols represent: α_0 = intercept; β_1 = regression slope if age $< \gamma_1$; γ_1 = first breakpoint; β_2 = regression slope if $\gamma_1 \leq$ age $< \gamma_2$; γ_2 = second
379 breakpoint; β_3 = regression slope if $\gamma_2 \leq$ age.

380 CI, 95% confidence interval; CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; n, number; o, observations; subj, subjects

381

382 Discussion

383 This prospective longitudinal study established comprehensive trajectories of a combined set of
384 muscle impairments, consisting of muscle strength, contractures, and muscle size alterations, in the
385 same cohort of growing boys with DMD. We adjusted for typical strength development, ROM reduction
386 and muscle growth observed in TD by calculating unit-less z-scores in reference to TD peers. Therefore,
387 the established trajectories solely reflect pathological changes. This is the first study to describe
388 longitudinal trajectories for muscle impairments expressed as deficits or alterations in reference to TD.
389 The use of these unit-less z-scores allows for the comparison of pathological involvement between
390 muscle groups and different muscle impairments.

391
392 Muscle weakness in growing boys with DMD follows a non-linear longitudinal trajectory, illustrating
393 that its progression is more complex than a continuous increase. Initially, muscle strength improved
394 (for hip flexion) or remained stable (for all other muscle groups) and then declined after 6.6-9.5 years.
395 Lerario et al. also described muscle weakness at the knee as piecewise trends with initial improvements
396 before 7.5 years of age and declines after. The initial improvement or stable period is consistent with
397 the commonly held concept of the “honeymoon” period in DMD [62,63]. However, our results
398 indicated that boys with DMD are already weaker than TD children at young ages, which aligns with
399 previous literature [28–30]. Between muscle groups, the largest initial deficit was found for hip
400 extension strength, followed by hip flexion, dorsiflexion, hip abduction, plantar flexion, knee flexion,
401 and lastly knee extension strength. This only partially conforms with the known pattern of proximal to
402 distal muscle weakness in DMD, since, unexpectedly, the ankle muscles were initially weaker than the
403 knee muscles. After the initial improvement or stable period, the strength deficit progression rate
404 changed to a decline at a certain age (i.e. breakpoint). Among muscle groups, this age did increase
405 according to the proximal to distal pattern of muscle weakness (with exception of hip abduction and
406 knee flexion). Indeed, hip extension and flexion strength began to decline at an earlier age than knee

407 extension strength, which was followed by ankle dorsiflexion and plantar flexion strength. Yet, the
408 decline rate was not compatible with this pattern. Specifically, knee extension strength showed the
409 steepest decline, followed by hip abduction, plantar flexion, dorsiflexion, hip extension and flexion,
410 and knee flexion strength. The variations in decline rate among muscle groups can be partially
411 attributed to the timing of the breakpoint and the existing initial weakness. Previous literature
412 reported a similar sequence of decline rate among muscle groups [32,33]. However, the longitudinal
413 trajectories are not entirely equivalent, but due to methodological discrepancies among the studies,
414 comparing the results proves challenging. Our results showed a flattening of the deterioration for hip
415 extension, hip flexion and knee extension strength through the linear models (S1 Fig and S1 Table).
416 Such a ceiling effect has also been reported by previous literature, as muscles can only degenerate
417 until a certain point [24,47].

418
419 The trajectories of the ROMs revealed a clear decline solely for ankle dorsiflexion. In DMD, ankle
420 plantar flexion contractures are the first contractures to develop, and, hence, occur more frequently
421 and severely than hip and knee contractures in the ambulatory period [24,35]. Our results indicated
422 already important plantar flexion contractures at young ages, which further progressively increased
423 after the age of 8 years. Larger deficits were observed for dorsiflexion ROM with knee extended than
424 with knee flexed, suggesting that the gastrocnemius is more affected than the soleus in the boys with
425 DMD. Previous literature found that the absolute dorsiflexion ROM declined linearly from early ages
426 onwards [32,37], which is in contrast with the non-linear piecewise trajectories in the current results.
427 Although the observed decline rates in absolute dorsiflexion ROM were steeper than the previously
428 reported longitudinal results of Kiefer et al. [37], the boys with DMD in the current study lost the ability
429 to achieve neutral ankle angles at approximately 12 years of age with knee extended and at
430 approximately 14 years of age with knee flexed, which was at an older age than reported by Leon et
431 al.[32]. The proactive/preventive policy of addressing contractures with the early use of night-time
432 AFOs and occasional serial casting may have played an important role in retaining dorsiflexion ROM

433 during the initial stable phase and in delaying the inability to achieve neutral ankle angles. In contrast
434 to the distal plantar flexion contractures, proximal lower-extremity contractures develop slowly in the
435 ambulatory period but tend to progress rapidly after transitioning to the wheelchair [8,24,35]. The
436 data exploration of absolute hip extension ROM and, absolute and unit-less hip adduction ROMs
437 suggested a subtle downward trend (S5 Fig). Hip extension ROM already showed deficits in young
438 children, indicating early hip flexion contractures, but subsequently declined at a similar rate to that
439 observed in TD. Hip adduction ROM declined more rapidly than in TD children, yet it did not exhibit
440 large deficits initially, implying that hip abduction contractures are absent early on but could develop
441 after loss of ambulation. Although knee extension ROM did not progress with age and no deficit with
442 respect to TD was found on average, there was significant inter-subject variability, and three patients
443 presented with evident knee flexion contractures. Deficits in the hamstrings ROM were shown in young
444 children, reflecting early hamstrings contractures, but subsequently, the ROM slightly tended to catch
445 up that in TD children.

446
447 The trajectories of the muscle size alterations were muscle-specific, which aligns with previous
448 literature [9]. Our results indicated that the m. rectus femoris CSA was slightly increased with respect
449 to TD at young ages, but showed a decrease from the age of 8.8 years onwards, resulting in atrophy at
450 older ages. This aligns with the cross-sectional findings of Mathur et al.[28], who observed hypertrophy
451 of the m. quadriceps under the age of 10 years and atrophy from the age of 11 years. In contrast, our
452 results indicated obvious hypertrophy in the m. medial gastrocnemius, however with a decrease from
453 9.5 years of age. (Pseudo)hypertrophy is a well-known symptom of DMD and has been repeatedly
454 reported by previous studies [9,28,49]. Morse et al.[51] is, to the best of our knowledge, the only study
455 that reported atrophy of m. medial gastrocnemius, though in adults with DMD. Hence, our observed
456 trajectory of the m. medial gastrocnemius CSA, i.e. decreasing hypertrophy, may result in atrophy at
457 adult ages. Although the m. rectus femoris and m. medial gastrocnemius CSAs displayed similar
458 longitudinal trajectories, both muscles were characterized by different pathological processes (i.e., m.

459 rectus femoris atrophy vs m. medial gastrocnemius hypertrophy), a finding also reported by the cross-
460 sectional study of Wokke et al. [9]. In line with the observations of Wokke et al. [9], the trajectory of
461 m. tibialis anterior CSA appeared less clearly defined with a high inter-subject variability.

462

463 This study provided novel insights by combining a set of different muscle impairments from multiple
464 muscle groups as well as by expressing them as deficits or alterations in reference to TD, thereby solely
465 revealing the pathological trajectories. Overall, the pathological trajectories of most muscle
466 impairments with age followed a similar non-linear, piecewise pattern, characterized by an initial
467 phase of improvement or stability lasting until 6.6-9.5 years, and a subsequent decline after these ages.

468 This indicates that despite the progressive nature of DMD, the deterioration of muscle impairments is
469 more complex than a steady decline. There is a period in which there is no deterioration (i.e.,
470 honeymoon). Both the start of corticosteroids and the preventive use of night-time AFOs may
471 potentially play a significant role in this period of stability. However, all muscle strength outcomes
472 (except knee extension) and several ROMs, i.e., hip extension, m. hamstrings and ankle dorsiflexion
473 ROMs, showed already initial deficits in reference to TD early on at young ages. These proximal
474 contractures were already present in young boys with DMD, but did not further decline with age during
475 the ambulatory period. Conversely, general muscle weakness and plantar flexion contractures were
476 the most important muscle impairments that exhibited the steepest deteriorations after the initial
477 period of stability, resulting in large deficits at older ages. Moreover, the longitudinal trajectories of
478 deficits in muscle impairments appeared to be coupled. As such, it is interesting to note the decline in
479 muscle strength, ROM and CSA around the ankle, which all started around 8-9 years of age.

480

481 Although this study improved the insights into the longitudinal trajectories of muscle impairments in
482 DMD based on a unique mixed longitudinal dataset, there were some limitations. The children with
483 DMD enrolled in the study at different ages and the baseline age range was wide. Additionally, a limited
484 number of repeated assessments was collected in some of the children with DMD. Moreover, the inter-

485 subject heterogeneity was high due to the differences in medical and clinical background such as
486 clinical trial participation, adherence to night-time AFOs, periods of serial casting, functional level, etc.
487 (S4 Fig). More data is needed to delineate the influence of these background differences on the
488 longitudinal trajectories. For the strength measurements, we were dependent on the cooperation and
489 motivation of the children. Caution is needed with the interpretation of the unit-less ROMs
490 trajectories, as they were calculated based on age categories, which could result in abrupt changes in
491 the unit-less ROMs with age. This highlights the need for TD percentile curves for ROMs to aid in
492 distinguishing pathological reductions in ROM from the typical reduction in ROM during growth. Lastly,
493 the sample size of the ultrasound dataset was small, especially for the m. rectus femoris, since we were
494 unable to process the data of some older patients with DMD due to muscle border invisibility caused
495 by severe muscle degeneration. Therefore, the results of ultrasound dataset should be interpreted
496 with caution.

497

498 Despite the limitations, this study has established longitudinal trajectories of muscle impairments,
499 consisting of muscle strength, contractures and muscle size alterations, in a cohort of growing boys
500 with DMD covering the ambulation period. These longitudinal trajectories are valuable for enhancing
501 our understanding of the relationship between muscle impairments and progressive gait pathology in
502 DMD. Moreover, the results revealed sensitive outcome measures, which could enhance clinical trial
503 design to detect the efficacy of novel therapeutic strategies.

504 Acknowledgments

505 The authors wish to thank all the children and parents for their participation in this study. We also
506 thank the colleagues of the University Hospital of Leuven involved in the recruitment. A special thank
507 you to Elze Stoop and Ester Huyghe for their support in data collection and processing.

508 References

- 509 1. Sutherland DH, Olshen R, Cooper L, Wyatt M, Leach J, Mubarak S, et al. The pathomechanics
510 of gait in Duchenne Muscular Dystrophy. *Dev Med Child Neurol*. 1981;23: 3–22.
511 doi:10.1111/j.1469-8749.1981.tb08442.x
- 512 2. Sussman M. Duchenne Muscular Dystrophy. *J Am Acad Orthop Surg*. 2002;10: 138–51.
513 doi:10.5435/00124635-200203000-00009
- 514 3. Emery AEH. Population Frequencies of Inherited Neuromuscular diseases -a World Survey.
515 *Neuromuscul Disord*. 1991;1: 19–29. doi:10.1016/0960-8966(91)90039-u
- 516 4. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the
517 sarcolemma from stresses developed during muscle contraction. *Proc Natl Acad Sci U S A*.
518 1993;90: 3710–4. doi:10.1073/pnas.90.8.3710
- 519 5. Moens P, Baatsen PHWW, Maréchal G. Increased susceptibility of EDL muscles from mdx mice
520 to damage induced by contraction with stretch. *J Muscle Res Cell Motil*. 1993;14: 446–51.
521 doi:10.1007/BF00121296
- 522 6. Lindsay A, Baumann CW, Rebbeck RT, Yuen SL, Southern WM, Hodges JS, et al. Mechanical
523 factors tune the sensitivity of mdx muscle to eccentric strength loss and its protection by
524 antioxidant and calcium modulators. *Skelet Muscle*. 2020;10: 3. doi:10.1186/s13395-020-
525 0221-2
- 526 7. Jones D, Round J, de Haan A. Skeletal muscles, from molecules to movement. A textbook of
527 muscle physiology for sport exercise, physiotherapy and medicine. London, UK: Elsevier; 2010.
- 528 8. Skalsky AJ, McDonald CM. Prevention and management of limb contractures in
529 neuromuscular diseases. *Phys Med Rehabil Clin N Am*. 2012;23: 675–87.
530 doi:10.1016/j.pmr.2012.06.009
- 531 9. Wokke BH, van den Bergen JC, Versluis MJ, Niks EH, Milles J, Webb AG, et al. Quantitative MRI
532 and strength measurements in the assessment of muscle quality in Duchenne muscular
533 dystrophy. *Neuromuscul Disord*. 2014;24: 409–16. doi:10.1016/j.nmd.2014.01.015
- 534 10. Goemans N, Signorovitch J, McDonald C, Mercuri E, Niks E, Wong B, et al. Functional
535 trajectories of upper limb and pulmonary function before and after loss of ambulation in
536 Duchenne muscular dystrophy. *Neuromuscul Disord*. 2021;31: S47–S162.
537 doi:10.1016/j.nmd.2021.07.148
- 538 11. Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and
539 management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular,
540 rehabilitation, endocrine, and gastrointestinal and nutritional management. *Lancet*
541 *Neurology*. 2018. pp. 251–267. doi:10.1016/S1474-4422(18)30024-3
- 542 12. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and
543 management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and
544 psychosocial management. *Lancet Neurol*. 2010;9: 77–93. doi:10.1016/S1474-4422(09)70271-
545 6
- 546 13. Kieny P, Chollet S, Delalande P, Le Fort M, Magot A, Pereon Y, et al. Evolution of life
547 expectancy of patients with Duchenne muscular dystrophy at AFM Yolaine de Kepper centre
548 between 1981 and 2011. *Ann Phys Rehabil Med*. 2013;56: 443–54.
549 doi:10.1016/j.rehab.2013.06.002
- 550 14. Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmüller H. Life expectancy
551 at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. *Eur J*

- 552 Epidemiol. 2020;35: 643–653. doi:10.1007/s10654-020-00613-8
- 553 15. Rideau Y, Duport G, Delaubrier A, Guillou C, Renardel-Irani A, Bach J. Early treatment to
554 preserve quality of locomotion for children with Duchenne muscular dystrophy. *Semin*
555 *Neurol.* 1995;15: 9–17. doi:10.1055/s-2008-1041001
- 556 16. Bakker JPJ, de Groot IJM, Beckerman H, de Jong BA, Lankhorst GJ. The effects of knee-ankle-
557 foot orthoses in the treatment of Duchenne muscular dystrophy: Review of the literature. *Clin*
558 *Rehabil.* 2000;14: 343–59. doi:10.1191/0269215500cr319oa
- 559 17. Khodadadeh S, McClelland MR, Patrick JH, Edwards RHT, Evans GA. Knee Moments in
560 Duchenne Muscular Dystrophy. *Lancet.* 1986;2: 544–5. doi:10.1016/s0140-6736(86)90114-5
- 561 18. de Souza MA, Figueiredo MML, de Baptista CRDJA, Aldaves RD, Mattiello-Sverzut AC.
562 Beneficial effects of ankle-foot orthosis daytime use on the gait of Duchenne muscular
563 dystrophy patients. *Clin Biomech.* 2016;35: 102–110. doi:10.1016/j.clinbiomech.2016.04.005
- 564 19. Eagle M. Report on the Muscular Dystrophy Campaign workshop: Exercise in neuromuscular
565 diseases Newcastle, January 2002. *Neuromuscul Disord.* 2002;12: 975–83. doi:10.1016/s0960-
566 8966(02)00136-0
- 567 20. Markati T, Oskoui M, Farrar MA, Duong T, Goemans N, Servais L. Emerging therapies for
568 Duchenne muscular dystrophy. *Lancet Neurol.* 2022;21: 814–829. doi:10.1016/S1474-
569 4422(22)00125-9
- 570 21. Ricci G, Bello L, Torri F, Schirinzi E, Pegoraro E, Siciliano G. Therapeutic opportunities and
571 clinical outcome measures in Duchenne muscular dystrophy. *Neurol Sci.* 2022;43: 625–633.
572 doi:10.1007/s10072-022-06085-w
- 573 22. Goemans N, Van den Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory
574 Analysis Project (cTAP). Individualized prediction of changes in 6-minute walk distance for
575 patients with Duchenne muscular dystrophy. *PLoS One.* 2016;11: e0164684.
576 doi:10.1371/journal.pone.0164684
- 577 23. Goemans N. Therapy development and clinical outcome measures for Duchenne muscular
578 dystrophy [PhD thesis]. Leuven: KU Leuven; 2013.
- 579 24. McDonald CM, Abresch RT, Carter GT, Fowler WM, Johnson ER, Kilmer DD, et al. Profiles of
580 Neuromuscular Diseases. Duchenne Muscular Dystrophy. *Am J Phys Med Rehabil.* 1995;74:
581 S70-92. doi:10.1097/00002060-199509001-00003
- 582 25. Escolar DM, Henricson EK, Mayhew J, Florence J, Leshner R, Patel KM, et al. Clinical evaluator
583 reliability for quantitative and manual muscle testing measures of strength in children. *Muscle*
584 *and Nerve.* 2001;24: 787–93. doi:10.1002/mus.1070
- 585 26. Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, et al. Reliable
586 surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.
587 *Muscle and Nerve.* 2007;35: 36–42. doi:10.1002/mus.20654
- 588 27. Bohannon RW. Manual muscle testing: does it meet the standards of an adequate screening
589 test? *Clin Rehabil.* 2005;19: 662–7. doi:10.1191/0269215505cr873oa
- 590 28. Mathur S, Lott DJ, Senesac C, Germain SA, Vohra RS, Sweeney HL, et al. Age-Related
591 Differences in Lower-Limb Muscle Cross-Sectional Area and Torque Production in Boys With
592 Duchenne Muscular Dystrophy. *Arch Phys Med Rehabil.* 2010;91: 1051–8.
593 doi:10.1016/j.apmr.2010.03.024
- 594 29. Buckon C, Sienko S, Bagley A, Sison M, Fowler E, Staudt L, et al. Can Quantitative Muscle
595 Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids
596 in Ambulatory Boys with Duchenne Muscular Dystrophy? *PLoS Curr.* 2016;8:

- 597 ecurrents.md.1ced64dff945f8958221fddcd4ee60b0.
598 doi:10.1371/currents.md.1ced64dff945f8958221fddcd4ee60b0
- 599 30. Beenakker EAC, Maurits NM, Fock JM, Brouwer OF, van der Hoeven JH. Functional ability and
600 muscle force in healthy children and ambulant Duchenne muscular dystrophy patients. *Eur J*
601 *Paediatr Neurol.* 2005;9: 387–93. doi:10.1016/j.ejpn.2005.06.004
- 602 31. Lerario A, Bonfiglio S, Sormani M, Tettamanti A, Marktél S, Napolitano S, et al. Quantitative
603 muscle strength assessment in duchenne muscular dystrophy : longitudinal study and
604 correlation with functional measures. *BMC Neurol.* 2012;12: 91. doi:doi: 10.1186/1471-2377-
605 12-91
- 606 32. Leon M, Roza D, Davoli G, Baptista C, Sobreira C, Mattiello-Sverzut A. Generation of percentile
607 curves for strength and functional abilities for boys with Duchenne muscular dystrophy.
608 *Muscle and Nerve.* 2023;68: 198–205. doi:10.1002/mus.27921
- 609 33. Buckon CE, Sienko SE, Fowler EG, Bagley AM, Staudt LA, Sison-Williamson M, et al. A
610 Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in
611 Ambulatory Boys with Duchenne Muscular Dystrophy. *J Neuromuscul Dis.* 2022;9: 321–334.
612 doi:10.3233/JND-210704
- 613 34. Willcocks RJ, Barnard AM, Wortman RJ, Senesac CR, Lott DJ, Harrington AT, et al.
614 Development of Contractures in DMD in Relation to MRI-Determined Muscle Quality and
615 Ambulatory Function. *J Neuromuscul Dis.* 2022;9: 289–302. doi:10.3233/JND-210731
- 616 35. Choi Y-A, Chun S-M, Kim Y, Shin H-I. Lower extremity joint contracture according to
617 ambulatory status in children with Duchenne muscular dystrophy. *BMC Musculoskelet Disord.*
618 2018;19: 287. doi:10.1186/s12891-018-2212-6
- 619 36. McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of
620 glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular
621 dystrophy: a prospective cohort study. *Lancet.* 2018;391: 451–461. doi:10.1016/S0140-
622 6736(17)32160-8
- 623 37. Kiefer M, Bonarrigo K, Quatman-Yates C, Fowler A, Horn PS, Wong BL. Progression of Ankle
624 Plantarflexion Contractures and Functional Decline in Duchenne Muscular Dystrophy:
625 Implications for Physical Therapy Management. *Pediatr Phys Ther.* 2019;31: 61–66.
626 doi:10.1097/PEP.0000000000000553
- 627 38. Mudge AJ, Bau K V., Purcell LN, Wu JC, Axt MW, Selber P, et al. Normative reference values for
628 lower limb joint range, bone torsion, and alignment in children aged 4-16 years. *J Pediatr*
629 *Orthop Part B.* 2014;23: 15–25. doi:10.1097/BPB.0b013e328364220a
- 630 39. Sankar WN, Laird CT, Baldwin KD. Hip range of motion in children: What is the norm? *J Pediatr*
631 *Orthop.* 2012;32: 399–405. doi:10.1097/BPO.0b013e3182519683
- 632 40. Lee SY, Lee SH, Chung CY, Park MS, Lee KM, Akhmedov B, et al. Age-related changes in
633 physical examination and gait parameters in normally developing children and adolescents. *J*
634 *Pediatr Orthop Part B.* 2013;22: 153–7. doi:10.1097/BPB.0b013e32835b2e7f
- 635 41. Sherlock SP, Palmer J, Wagner KR, Abdel-Hamid HZ, Bertini E, Tian C, et al. Quantitative
636 magnetic resonance imaging measures as biomarkers of disease progression in boys with
637 Duchenne muscular dystrophy: a phase 2 trial of domagrozumab. *J Neurol.* 2022;269: 4421–
638 4435. doi:10.1007/s00415-022-11084-0
- 639 42. Sherlock SP, Zhang Y, Binks M, Marraffino S. Quantitative muscle MRI biomarkers in Duchenne
640 muscular dystrophy: cross-sectional correlations with age and functional tests. *Biomark Med.*
641 2021;15: 761–773. doi:10.2217/bmm-2020-0801

- 642 43. Godi C, Ambrosi A, Nicastro F, Previtali SC, Santarosa C, Napolitano S, et al. Longitudinal MRI
643 quantification of muscle degeneration in Duchenne muscular dystrophy. *Ann Clin Transl*
644 *Neurol.* 2016;3: 607–22. doi:10.1002/acn3.319
- 645 44. Nagy S, Schädelin S, Hafner P, Bonati U, Scherrer D, Ebi S, et al. Longitudinal reliability of
646 outcome measures in patients with Duchenne muscular dystrophy. *Muscle and Nerve.*
647 2020;61: 63–68. doi:10.1002/mus.26690
- 648 45. Ropars J, Gravot F, Ben Salem D, Rousseau F, Brochard S, Pons C. Muscle MRI: A biomarker of
649 disease severity in Duchenne muscular dystrophy? A systematic review. *Neurology.* 2020;94:
650 117–133. doi:10.1212/WNL.0000000000008811
- 651 46. Vill K, Sehri M, Müller C, Hannibal I, Huf V, Idriess M, et al. Qualitative and quantitative muscle
652 ultrasound in patients with Duchenne muscular dystrophy: Where do sonographic changes
653 begin? *Eur J Paediatr Neurol.* 2020;28: 142–150. doi:10.1016/j.ejpn.2020.06.001
- 654 47. Jansen M, van Alfen N, Nijhuis van der Sanden MWG, van Dijk JP, Pillen S, de Groot IJM.
655 Quantitative muscle ultrasound is a promising longitudinal follow-up tool in Duchenne
656 muscular dystrophy. *Neuromuscul Disord.* 2012;22: 306–17. doi:10.1016/j.nmd.2011.10.020
- 657 48. Zaidman CM, Malkus EC, Connolly AM. Muscle Ultrasound Quantifies Disease Progression
658 Over Time in Infants and Young Boys with Duchenne Muscular Dystrophy. *Muscle Nerve.*
659 2015;52: 334–8. doi:10.1002/mus.24609
- 660 49. Bulut N, Karaduman A, Alemdaroğlu-Gürbüz İ, Yılmaz Ö, Topaloğlu H, Özçakar L.
661 Ultrasonographic assessment of lower limb muscle architecture in children with early-stage
662 Duchenne muscular dystrophy. *Arq Neuropsiquiatr.* 2022;80: 475–481. doi:10.1590/0004-
663 282X-ANP-2021-0038
- 664 50. Pillen S, Verrips A, van Alfen N, Arts IMP, Sie LTL, Zwarts MJ. Quantitative skeletal muscle
665 ultrasound: Diagnostic value in childhood neuromuscular disease. *Neuromuscul Disord.*
666 2007;17: 509–16. doi:10.1016/j.nmd.2007.03.008
- 667 51. Morse CI, Smith J, Denny A, Tweedale J, Searle ND. Gastrocnemius medialis muscle
668 architecture and physiological cross sectional area in adult males with Duchenne muscular
669 dystrophy. *J Musculoskelet Neuronal Interact.* 2015;15: 154–60.
- 670 52. Vandekerckhove I, Hanssen B, Peeters N, Dewit T, De Beukelaer N, Van den Hauwe M, et al.
671 Anthropometric-related percentile curves for muscle size and strength of lower limb muscles
672 of typically developing children. *medRxiv Prepr.* 2024. doi:10.1101/2024.03.27.24304866
- 673 53. Goudriaan M, Nieuwenhuys A, Schless S, Goemans N, Molenaers G, Desloovere K. A new
674 strength assessment to evaluate the association between muscle weakness and gait
675 pathology in children with cerebral palsy. *PLoS One.* 2018;13: e0191097.
676 doi:10.1371/journal.pone.0191097
- 677 54. Verreydt I, Vandekerckhove I, Stoop E, Peeters N, van Tittelboom V, Van de Walle P, et al.
678 Instrumented strength assessment in typically developing children and children with a neural
679 or neuromuscular disorder: A reliability, validity and responsiveness study. *Front Physiol.*
680 2022;13: 855222. doi:10.3389/fphys.2022.855222
- 681 55. Cenni F, Monari D, Desloovere K, Aertbeliën E, Schless SH, Bruyninckx H. The reliability and
682 validity of a clinical 3D freehand ultrasound system. *Comput Methods Programs Biomed.*
683 2016;136: 179–87. doi:10.1016/j.cmpb.2016.09.001
- 684 56. Hanssen B, Peeters N, Dewit T, Huyghe E, Dan B, Molenaers G, et al. Reliability of 3D freehand
685 ultrasound to assess lower limb muscles in children with spastic cerebral palsy and typical
686 development. *J Anat.* 2023;242: 986–1002. doi:10.1111/joa.13839

- 687 57. Cenni F, Schless SH, Monari D, Bar-On L, Aertbeliën E, Bruyninckx H, et al. An innovative
688 solution to reduce muscle deformation during ultrasonography data collection. *J Biomech.*
689 2018;77: 194–200. doi:10.1016/j.jbiomech.2018.06.002
- 690 58. Peeters N, Hanssen B, De Beukelaer N, Vandekerckhove I, Walhain F, Huyghe E, et al. A
691 comprehensive normative reference database of muscle morphology in typically developing
692 children aged 3–18 years—a cross-sectional ultrasound study. *J Anat.* 2023;242: 754–770.
693 doi:10.1111/joa.13817
- 694 59. Vandekerckhove I, Van den Hauwe M, De Beukelaer N, Stoop E, Goudriaan M, Delporte M, et
695 al. Longitudinal Alterations in Gait Features in Growing Children With Duchenne Muscular
696 Dystrophy. *Front Hum Neurosci.* 2022;16: 861136. doi:10.3389/fnhum.2022.861136
- 697 60. Verbeke G, Molenberghs G. *Linear mixed models for longitudinal data.* New-York: Springer
698 Series in Statistics, Springer-Verlag; 2000.
- 699 61. Verbeke G, Molenberghs G. *Linear mixed models in practice: a SAS-oriented approach.* New
700 York: Springer; 1997.
- 701 62. Connolly A, Florence J, Cradock M, Eagle M, Flanigan K, McDonald C, et al. One year outcome
702 of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler
703 development. *Pediatr Neurol.* 2014;50: 557–63. doi:10.1016/j.pediatrneurol.2014.02.006
- 704 63. Henricson E, Abresch R, Han JJ, Nicorici A, Keller EG, Elfring G, et al. Percent-predicted 6-
705 minute walk distance in duchenne muscular dystrophy to account for maturational influences.
706 *PLoS Curr.* 2012;4: RRN1297. doi:10.1371/currents.RRN1297

707 Supporting information

708 **S1 Fig. Predicted longitudinal trajectories for muscle strength deficits of hip muscles (a), knee**
709 **muscles (b) and ankle muscles (c) with age for boys with DMD of linear mixed effect models.** The
710 average predicted trajectory (black thick line), the individual predicted profiles (colored thinner lines),
711 and the actual observed outcomes (colored dots) are displayed. Each color represents one patient with
712 DMD. The estimates for the fixed effects are given in Supplementary Table 1. DMD, Duchenne
713 muscular dystrophy

714

715 **S1 Table. Fixed effects of linear mixed effect models for the longitudinal trajectories of the muscle**
716 **strength deficits with age for boys with DMD**

717 p-values in bold indicate significance level at $p < 0.05$.

718 The following symbols represent: α_0 = intercept; β_1 = regression slope of age; β_2 = regression slope of
719 age²; β_3 = regression slope of age³.

720 CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; subj,
721 subjects

722

723 **S2 Fig. Predicted longitudinal trajectories for absolute (left column) and non-dimensional (right**
724 **column) knee extension ROM (a), Hamstrings ROM (b), ankle dorsiflexion with knee extended (c)**
725 **and ankle dorsiflexion with knee flexed (d) with age for boys with DMD of linear mixed effect**
726 **models.** The average predicted trajectory (black thick line), the individual predicted profiles (colored
727 thinner lines), and the actual observed outcomes (colored dots) are displayed. Each color represents
728 one patient with DMD. The estimates for the fixed effects are given in Supplementary Table 2. DMD,
729 Duchenne muscular dystrophy; ROM, range of motion.

730

731 **S2 Table. Fixed effects of linear mixed effect models for the longitudinal trajectories of the absolute**
732 **and non-dimensional ROMs with age for boys with DMD**

733 p-values in bold indicate significance level at $p < 0.05$.

734 The following symbols represent: α_0 = intercept; β_1 = regression slope of age; β_2 = regression slope of
735 age²; β_3 = regression slope of age³.

736 CI, 95% confidence interval; DMD, Duchenne muscular dystrophy; n, number; o, observations; ROM,
737 range of motion; subj, subjects

738

739 **S3 Fig. Predicted longitudinal trajectories for muscle size deficits with age for boys with DMD of**
740 **linear mixed effect models.** The average predicted trajectory (black thick line), the individual predicted
741 profiles (colored thinner lines), and the actual observed outcomes (colored dots) are displayed. Each
742 color represents one patient with DMD. The estimates for the fixed effects are given in Supplementary
743 Table 3. DMD, Duchenne muscular dystrophy

744

745 **S3 Table. Fixed effects of linear mixed-effect models for the longitudinal trajectories of the muscle**
746 **size alterations with age for boys with DMD**

747 p-values in bold indicate significance level at $p < 0.05$.

748 The following symbols represent: α_0 = intercept; β_1 = regression slope of age; β_2 = regression slope of
749 age².

750 CI, 95% confidence interval; CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; n,
751 number; o, observations; subj, subjects

752

753 **S4 Fig. Overview of the participants medical and clinical background. Each color represents one**
754 **patient with DMD.**

755 AFO, ankle foot orthosis; DMD, Duchenne muscular dystrophy; LA, loss of ambulation

756

757 **S5 Fig. Data exploration of longitudinal trajectories for absolute (left column) and non-dimensional**
758 **(right column) hip extension ROM (a) and hip adduction ROM (b) with age for boys with DMD of**
759 **linear mixed effect models.** The Loess regression (black thick line) and the actual observed outcomes
760 (colored symbols) are displayed. Each color represents one patient with DMD. DMD, Duchenne
761 muscular dystrophy; ROM, range of motion.

762

763 **S4 Table. Estimates of random-effect and residual covariance structure of piecewise models for the**
764 **longitudinal trajectories of the muscle impairments with age for boys with DMD**

765 The following symbols represent: σ^2 =variance; a_{i0} = random intercept; b_i = random slope; b_{i1} = random
766 slope for regression slope before breakpoint; b_{i2} = random slope for regression slope after breakpoint;
767 ε_{ij} = measurement error.

768 CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; ROM, range of motion;

769

770 **S5 Table. Estimates of random-effect and residual covariance structure of linear mixed-effect models**
771 **for the longitudinal trajectories of the muscle impairments with age for boys with DMD**

772 The following symbols represent: σ^2 =variance; a_{i0} = random intercept; b_{i1} = random slope for regression
773 slope of age; ε_{ij} = measurement error.

774 CSA, cross-sectional area; DMD, Duchenne muscular dystrophy; ROM, range of motion;

775




Fig1




Fig2






Fig3